Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711392 | 0.94 | TRPM2 (0.59) | TRPM2 | |
| SCHEMBL20711297 | 0.94 | TRPM2 (0.65) | TRPM2ADORA2AADORA2BCYP1A2THPO | |
| SCHEMBL20711316 | 0.90 | TRPM2 (0.61) | TRPM2 | |
| SCHEMBL20711324 | 0.89 | CYP1A2 (0.57) | ADORA2AADORA2BCYP1A2THPO | |
| SCHEMBL2295419 | 0.84 | TRPM2 (0.69) | TRPM2 | |
| SCHEMBL20711203 | 0.84 | TRPM2 (0.66) | TRPM2 | |
| SCHEMBL20711322 | 0.83 | CYP1A2 (0.55) | ADORA2AADORA2BCYP1A2THPO | |
| SCHEMBL22837890 | 0.82 | TRPM2 (0.86) | TRPM2 | |
| SCHEMBL20711186 | 0.82 | TRPM2 (0.86) | TRPM2 | |
| SCHEMBL20711343 | 0.82 | ADORA2A (0.66) | ADORA2AADORA2BCYP1A2THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | TRPM2 2028/4885ADORA2A 5/4885ADORA2B 10/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | TRPM2 2028/4885ADORA2A 5/4885ADORA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.